Systematic treatment in unresectable hepatocellular carcinoma:The most concerns  

作　　者：Jian-Hong Zhong Kang Chen Ze Su Shao-Ping Liu Fan-Jian Zeng Lin Ye 

机构地区：[1]Department of Hepatobiliary Surgery,Guangxi Medical University Cancer Hospital,Nanning 530021,China [2]Department of Hepatobiliary Surgery,Second Affiliated Hospital of Guangxi Medical University,Nanning 530007,China [3]Department of Hepatobiliary Pancreatic Surgery,First People's Hospital of Nanning,Nanning 530016,China [4]Department of Hepatobiliary and Pancreatic Surgery,Eighth Affiliated Hospital of the Guangxi Medical University,Guigang 537100,China [5]Department of Hepatobiliary Surgery,Wuzhou Red Cross Hospital,Wuzhou 543002,China [6]Department of Hepatobiliary and Pancreatic Surgery,Affiliated Hospital of Guilin Medical University,Guilin 541002,China

出　　处：《iLIVER》2024年第3期1-4,共4页国际肝胆健康（英文）

基　　金：supported by the Guangxi key research and development plan(GuiKe AB24010082);the Specific Research Project of Guangxi for Research Bases and Talents(GuiKe AD22035057);Firstclass discipline innovation-driven talent program of Guangxi Medical University.

摘　　要：The most frequent causes of hepatocellular carcinoma(HCC)are chronic infection with hepatitis B or C virus,alcoholic liver disease,and fatty liver disease[1].The molecular pathological heterogeneity of HCC is obvious,which may be the main reason for the great difference in efficacy of different patients after receiving systematic therapy.

关 键 词：HEPATOCELLULAR liver CARCINOMA 

分 类 号：R735.7[医药卫生—肿瘤]